Glioma Markers

Gliomas are one of the most aggressive and lethal solid tumors of the central nervous system. Despite the alarming numbers, the molecular pathogenetic mechanisms of gliomas are not yet fully elucidated. Nowadays, several approaches aim to understand the biology of the disease and identify promising markers, which may provide effective novel therapies.

Brain tumors comprise approximately 2% of all adult cancers but form a larger fraction within the group of childhood tumors. Gliomas account for about 80% of all malignant brain tumors and are classified according to the cell type of origin, differentiation, and malignancy grade. Gliomas show considerable variability in age of onset, grade of severity, histological features, and ability to progress, as well as to metastasize

 
Download the Glioma Markers white paper

The white paper summarizes the recent developments in glioma classification and the key molecular markers for glioma stratification. Next, it highlights the glioma proteome with a list of relevant genes with favorable and unfavorable prognostic values in glioma. It then focuses on the glioma tumor microenvironment that may provide helpful insights when developing novel therapeutic strategies.

Learning points:

• The most common form of glioma - astrocytoma
• Glioma classification and key molecular pathology
• Adult and pediatric gliomas: distinctive features
• The glioma proteome
• The glioma tumor microenvironment
• Immunomodulation
• Angiogenesis
• Glioma cancer stem cells and drug resistance
• Chi3l1 as a modulator of stem cells' cellular states
• References